Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm

Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) is a Swedish late-stage pharmaceutical company committed to improving the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide. The company is targeting two main clinical indications; GERD (Gastroesophageal reflux disease) and H. pylori infection.

Cinclus Pharmas’ drug candidate, linaprazan glurate, is a proprietary prodrug of the molecule linaprazan, originally developed by AstraZeneca. Linaprazan glurate represents a new mode of action for the treatment of erosive gastroesophageal reflux disease, where there is currently a lack of sufficiently effective treatment options. The listing of Cinclus Pharma on Nasdaq Stockholm is an important milestone that enables continued development of linaprazan glurate.

Commenting on the listing, Nina Rawal, Partner at Trill Impact Advisory and Co-head of Trill Impact Ventures said::

“It is of course very exciting to see Cinclus Pharma being listed on Nasdaq Stockholm today. To us, the fact that Cinclus Pharma has managed to attract investor interest in the current financial climate, is a great testament to the quality of the asset and the strong management team. When Trill Impact invested in Cinclus Pharma a couple of years back, we were confident that the company had the potential to become a global leader in the treatment of severe gastric acid-related disease. Since then, the company has reported strong Phase II data and is now ready to move into the final stage of clinical development. We view Cinclus Pharma as a great example of a company where financial and social returns go hand in hand and lwe ook forward to continuing supporting the company’s development ahead.”

Christer Ahlberg, CEO of Cinclus Pharma, comments:

"We are very excited about this important step in Cinclus Pharma’s development. By becoming the product that can offer 24-hour acid control and healing for the most severely ill patients with eGERD, our drug candidate linaprazan glurate has the potential to drive a paradigm shift in the treatment of gastric acid-related diseases. There is a great need for a more effective treatment of gastric acid-related diseases, which makes Cinclus Pharma very well positioned to create value for our shareholders”

The IPO will, provided that the offering is fully subscribed, and that the over-allotment option is exercised in full, provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs. Trill Impact Ventures remains the largest shareholder after the IPO that also included participation from existing shareholders the Fourth Swedish National Pension Fund (AP4) and Linc AB among others. Incoming investors include Platinum Asset Management, Hudson Bay Capital Management, and AXA Investment Managers.

This material has been prepared for informational purposes only and should not be considered to be a recommendation to buy or sell securities or as investment advice. All statements and opinions included herein are subject to change as economic and market conditions dictate. There can be no assurance that any views, outlooks, or forward-looking statements will come to pass.